

Genetics, Hypertension, and Cardiovascular Disease

By Mark Houston, MD

Complete References

1. Sinatra ST, Houston MC, Editors. Nutritional and Integrative Strategies in Cardiovascular Medicine. CRC Press, Boca Raton, FL, 2015.
2. Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation of gene expression. *Curr Opin Lipidol.* 2000;11(1):3–7.
3. McNiven EM, German JB, Slupsky CM. Analytical metabolomics: nutritional opportunities for personalized health. *J Nutr Biochem.* 2011;22(11):995–1002.
4. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. *N Engl J Med.* 2011;365(22):2098–2109.
5. Nuno NB, Heuberger R. Nutrigenetic associations with cardiovascular disease. *Rev Cardiovasc Med.* 2014;15(3):217–225.
6. Holdt LM, Teupser D. From genotype to phenotype in human atherosclerosis—recent findings. *Curr Opin Lipidol.* 2013;24(5):410–418.
7. Roberts R, Stewart AF. Genetics of coronary artery disease in the 21st century. *Clin Cardiol.* 2012;35(9):536–540.
8. Houston MC. *What Your Doctor May Not Tell You About Heart Disease.* Grand Central Press, New York, NY, 2012.
9. Houston M. The role of noninvasive cardiovascular testing, applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease. *Ther Adv Cardiovasc Dis.* 2018;12(3):85–108.
10. Houston MC. New concepts in cardiovascular disease. *J Restor Med.* 2013;2:30–44.
11. Webster AL, Yan MS, Marsden PA. Epigenetics and cardiovascular disease. *Can J Cardiol.* 2013;29(1):46–57.
12. Castañer O, Corella D, Covas MI, Sorlí JV, Subirana I, Flores-Mateo G, Nonell L, Bulló M, de la Torre R, Portolés O, Fitó M; PREDIMED study investigators. In vivo transcriptomic profile after a Mediterranean diet in high-cardiovascular risk patients: a randomized controlled trial. *Am J Clin Nutr.* 2013;98(3):845–853.
13. Konstantinidou V, Covas MI, Sola R, Fitó M. Up-to date knowledge on the in vivo transcriptomic effect of the Mediterranean diet in humans. *Mol Nutr Food Res.* 2013;57(5):772–783.
14. Corella D, Ordovás JM. How does the Mediterranean diet promote cardiovascular health? Current progress toward molecular mechanisms: gene-diet interactions at the genomic, transcriptomic, and epigenomic levels provide novel insights into new mechanisms. *Bioessays.* 2014;36(5):526–537.
15. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med.* 2013;368(14):1279–1290.
16. González-Guardia L, Yubero-Serrano EM, Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, Marin C, Camargo A, Delgado-Casado N Roche HM, Perez-Jimenez F, Brennan L, López-Miranda J. Effects of the



Genetics, Hypertension, and Cardiovascular Disease

Mediterranean diet supplemented with coenzyme q10 on metabolomic profiles in elderly men and women. *J Gerontol A Biol Sci Med Sci*. 2015;70(1):78–84.

17. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med*. 1997;336(16):1117–1124.
18. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med*. 2001;344(1):3–10.
19. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. *JAMA*. 1998 Dec 16;280(23):2001–2007.
20. Laffer CL, Elijovich F, Eckert GJ, Tu W, Pratt JH, Brown NJ. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. *J Am Soc Hypertens*. 2014;8(7):475–480.
21. Vanden Heuvel JP. Nutrigenomics and nutrigenetics of ω 3 polyunsaturated fatty acids. *Prog Mol Biol Transl Sci*. 2012;108:75–112.
22. Varela LM, Ortega-Gomez A, Lopez S, Abia R, Muriana FJ, Bermudez B. The effects of dietary fatty acids on the postprandial triglyceride-rich lipoprotein/apoB48 receptor axis in human monocyte/macrophage cells. *J Nutr Biochem*. 2013;24(12):2031–2039.
23. Silva S, Bronze MR, Figueira ME, Siwy J, Mischak H, Combet E, Mullen W. Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study. *Am J Clin Nutr*. 2015;101(1):44–54.
24. Costanza AC, Moscovitch SD, Faria Neto HC, Mesquita ET. Probiotic therapy with *Saccharomyces boulardii* for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. *Int J Cardiol*. 2015;179:348–350.
25. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. *Hypertension*. 2014 Oct;64(4):897–903.
26. Tuohy KM, Fava F, Viola R. The way to a man's heart is through his gut microbiota—dietary pro- and prebiotics for the management of cardiovascular risk. *Proc Nutr Soc*. 2014 May;73(2):172–185.
27. Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. *Mayo Clin Proc*. 2014 Jan;89(1):107–114.
28. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. *N Engl J Med*. 2011; 365(22):2098–2109.
29. Paloaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: a meta-analysis. *JAMA*. 2010;303:648–656.
30. Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, di Pietro N, Sturma M, Novelli V. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. *JAMA*. 2013 Aug 28;310(8):821–828.
31. Schaefer EJ. Lipoproteins, nutrition, and heart disease. *Am J Clin Nutr*. 2002;75(2):191–212.
32. Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, West SG. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. *Am J Clin Nutr*. 2011;93(2):243–252.

Genetics, Hypertension, and Cardiovascular Disease

33. Hall KT, Nelson CP, Davis RB, Buring JE, Kirsch I, Mittleman MA, Loscalzo J, Samani NJ, Ridker PM, Kapchuk TJ, Chasman DI. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. *Arterioscler Thromb Vasc Biol.* 2014;34(9):2160–2167.
34. Winter JP, Gong Y, Grant PJ, Wild CP. Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. *Coron Artery Dis.* 2003;14(2):149–153.
35. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ; AtheroGene Investigators. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. *N Engl J Med.* 2003;349(17):1605–1613.
36. Korkor MT, Meng FB, Xing SY, Zhang MC, Guo JR, Zhu XX, Yang P. Microarray analysis of differential gene expression profile in peripheral blood cells of patients with human essential hypertension. *Int J Med Sci.* 2011;8(2):168–179.
37. Harrap SB. Blood 38. Zhou L, Xi B, Wei Y, Shen W, Li Y. Meta-analysis of the association between the insertion/deletion polymorphism in ACE gene and coronary heart disease among the Chinese population. *J Renin Angiotensin Aldosterone Syst.* 2012;13(2):296–304.
38. Zhou L, Xi B, Wei Y, Shen W, Li Y. Meta-analysis of the association between the insertion/deletion polymorphism in ACE gene and coronary heart disease among the Chinese population. *J Renin Angiotensin Aldosterone Syst.* 2012;13(2):296–304.
39. Fernández-Llama P, Poch E, Oriola J, Botey A, Coll E, Darnell A, Rivera F, Revert L. Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. *Kidney Int.* 1998;53(6):1743–1747.
40. Gardemann A, Fink M, Stricker J, Nguyen QD, Humme J, Katz N, Tillmanns H, Hehrlein FW, Rau M, Haberbusch W. ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. *Atherosclerosis.* 1998;139(1):153–159.
42. Castellano M, Muiesan ML, Rizzoni D, Beschi M, Pasini G, Cinelli A, Salvetti M, Porteri E, Bettoni G, Kreutz R. Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study. *Circulation.* 1995;91(11):2721–2724.
43. Mesas AE, Leon-Muñoz LM, Rodriguez-Artalejo F, Lopez-Garcia E. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. *Am J Clin Nutr.* 2011;94(4):1113–1126.
44. Palatini P, Ceolotto G, Ragazzo F, Dorigatti F, Saladini F, Papparella I, Mos L, Zanata G, Santonastaso M. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. *J Hypertens.* 2009;27(8):1594–1601.
45. Armaly Z, Assady S, Abassi Z. Corin: a new player in the regulation of salt-water balance and blood pressure. *Curr Opin Nephrol Hypertens.* 2013;22(6):713–720.
46. Zhou Y, Wu Q. Corin in natriuretic peptide processing and hypertension. *Curr Hypertens Rep.* 2014;16(2):415.
47. Peng H, Zhang Q, Cai X, Liu Y, Ding J, Tian H, Chao X, Shen H, Jiang L, Jin J, Zhang Y. Association between high serum soluble corin and hypertension: a cross-sectional study in a general population of China. *Am J Hypertens.* 2015;28(9):1141–1149.
48. Fontana V, de Faria AP, Barbaro NR, Sabbatini AR, Modolo R, Lacchini R, Moreno H. Modulation of aldosterone levels by -344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension. *J Am Soc Hypertens.* 2014;8(3):146–151.

Genetics, Hypertension, and Cardiovascular Disease

49. Levinsson A, Olin AC, Björck L, Rosengren A, Nyberg F. Nitric oxide synthase (NOS) single nucleotide polymorphisms are associated with coronary heart disease and hypertension in the INTERGENE study. *Nitric Oxide*. 2014;39:1–7.
50. Sun B, Williams JS, Svetkey LP, Kolatkar NS, Conlin PR. Beta2-adrenergic receptor genotype affects the renin-angiotensin-aldosterone system response to the Dietary Approaches to Stop Hypertension (DASH) dietary pattern. *Am J Clin Nutr*. 2010;92(2):444–449.
51. Chen Q, Turban S, Miller ER, Appel LJ. The effects of dietary patterns on plasma renin activity: results from the Dietary Approaches to Stop Hypertension trial. *J Hum Hypertens*. 2012;26(11):664–669.
52. Laffer CL, Elijovich F, Eckert GJ, Tu W, Pratt JH, Brown NJ. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. *J Am Soc Hypertens*. 2014;8(7):475–480.
53. Ward NC, Tsai IJ, Barden A, van Bockxmeer FM, Puddey IB, Hodgson JM, Croft KD. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. *Hypertension*. 2008;51(5):1393–1398.
54. Sun Y, Liao Y, Yuan Y, Feng L, Ma S, Wei F, Wang M, Zhu F. Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen: results from the study of optimal treatment in hypertensive patients with anti-AT1-receptor autoantibodies trial. *J Am Soc Hypertens*. 2014;8(1):21–27.
55. Yang X, Sethi A, Yanek LR, Knapper C, Nordestgaard BG, Tybjaerg-Hansen A, Becker DM, Mathias RA, Remaley AT, Becker LC. SCARB1 gene variants are associated with the phenotype of combined high high-density lipoprotein cholesterol and high lipoprotein (a). *Circ Cardiovasc Genet*. 2016;9(5):408–418.
56. Mendoza S, Trencheska O King SM, Nelson RW, Nedelkov D, Krauss RM, Yassine HN. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions. *J Clin Lipidol*. 2017;11(1):224–233.
57. Wyler von Ballmoos MC, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis. *J Clin Lipidol*. 2015;9(4):498–510.
58. Zheng C. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. *Curr Opin Lipidol*. 2014;25(1):35–39.
59. Thomas GS, Voros S, McPherson JA, Lansky AJ, Winn ME, Bateman TM, Elashoff MR, Lieu HD, Johnson AM, Daniels SE, Ladapo JA, Phelps CE, Douglas PS, Rosenberg S. A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study. *Circ Cardiovasc Genet*. 2013;6(2):154–162.
60. McPherson JA, Davis K, Yau M, Beineke P, Rosenberg S, Monane M, Fredi JL. The clinical utility of gene expression testing on the diagnostic evaluation of patients presenting to the cardiologist with symptoms of suspected obstructive coronary artery disease: results from the IMPACT (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) trial. *Pathw Cardiol*. 2013;12(2):37–42.
61. Wingrove JA, Daniels SE, Sehnert AJ, Tingley W, Elashoff MR, Rosenberg S, Buellesfeld L, Grube E, Newby LK, Ginsburg GS, Kraus WE. Correlation of peripheral- blood gene expression with the extent of coronary artery stenosis. *Circ Cardiovasc Genet*. 2008;1(1):31–38.
62. Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, Voros S, Ellis SG, J Waksman R, McPherson JA, Lansky AJ, Topol EJ; PREDICT Investigators. Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. *Cardiovasc Transl Res*. 2012;5(3):366–374.

Genetics, Hypertension, and Cardiovascular Disease

63. Ganna A, Salihovic S, Sundström J, Broeckling CD, Hedman AK, Magnusson PK, Pedersen NL, Larsson A, Siegbahn A, Zilmer M, Prenti J, Arnlöv J, Lind L, Fall T, Ingelsson E. Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease. *PLoS Genet.* 2014;10(12): e1004801.
64. Granger CB, Newgard CB, Califf RM, Newby LK, Shah SH, Sun JL, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, Haynes C, Hauser ER, Kraus WE. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. *Am Heart J.* 2012;163(5):844–850.
65. Rizza S, Copetti M, Rossi C, Cianfarani MA, Zucchelli M, Luzi A, Pecchioli C, Porzio O, Di Cola G, Urbani A, Pellegrini F, Federici M. Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. *Atherosclerosis.* 2014;232(2):260–264.



TownsendLetter.com/get-involved